BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing ...

BERKELEY, Calif. and MAINZ, Germany - Mainz Biomed NV (NASDAQ:MYNZ), a company focused on early cancer detection diagnostics, has announced its return to compliance with Nasdaq's stockholders' equity ...

Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's ...

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements ...

Mainz Biomed N.V. qualifiziert sich wieder für die Notierung am Nasdaq Capital Market Für den Inhalt der Mitteilung ist der ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BERKELEY, US – MAINZ, Germany – January 27, 2025 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of ...

Mainz Biomed N.V. qualifiziert sich wieder für die Notierung am Nasdaq Capital Market BERKELEY, USA und MAINZ, Deutschland – 27. Januar 2025 — Mainz Biomed (NASDAQ:MYNZ) („Mainz Biomed ...

Mainz BioMed NV BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic ...

Emittent / Herausgeber: Mainz BioMed N.V. / Schlagwort (e): Sonstiges Mainz Biomed N.V. qualifiziert sich wieder für die Notierung am Nasdaq Capital Market 27.01.2025 / 14:01 CET/CEST Für den ...

Mainz Biomed NV (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...